Citations 2
Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307.
Paterson, Alexander , Lew, Danika L., Hayes, Daniel F. , Schubert, Mark, Poznak, Catherine Van , Dees, Elizabeth Claire , Messino, Michael J., Margolis, Jeffrey, Dakhil, Shaker R. , Chew, Helen K. , Livingston, Robert B., Gralow, Julie R. , Barlow, William E. , Stopeck, Alison , Hershman, Dawn L. , Clemons, Mark , Ingle, James N. , Falkson, Carla I. , Elias, Anthony , Hortobágyi, Gabriel N.
Journal of Clinical Oncology | March 8, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 503-503
SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: Comparison of toxicities and patient-stated preference for oral versus intravenous delivery.
Paterson, Alexander , Lew, Danika L., Hayes, Daniel F. , Schubert, Mark, Poznak, Catherine Van , Dees, Elizabeth Claire , Messino, Michael J., Margolis, Jeffrey, Dakhil, Shaker R. , Chew, Helen K. , Livingston, Robert B., Gralow, Julie R. , Barlow, William E. , Stopeck, Alison , Hershman, Dawn L. , Clemons, Mark , Ingle, James N. , Falkson, Carla I. , Elias, Anthony , Hortobágyi, Gabriel N.
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 558-558